FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAldeyra Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALDX
Aldeyra Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Aldeyra Therapeutics, Inc. (ALDX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALDX
ALDX
Aldeyra Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALDX
  1. Home
  2. Stocks
  3. Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

🇺🇸ALDX•NASDAQ

Aldeyra Therapeutics, Inc.

🇺🇸ALDX•NASDAQ
Market cap
$40.51M

Your view on ALDX

Mkt Cap
$40.51M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aldeyra Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Todd C. Brady
Headquarters
131 Hartwell Avenue, Lexington, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Todd C. Brady
Headquarters
131 Hartwell Avenue, Lexington, MA, US
Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.

It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.

The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Aldeyra Therapeutics, Inc.. Starting points for Aldeyra Therapeutics, Inc.: EPS -$0.32, beta 1.29 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Aldeyra Therapeutics, Inc.. Trailing twelve-month EPS for Aldeyra Therapeutics, Inc. stands at -$0.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$9.67average of analysts' targets
Current price—

Buy

Targets, low to high

$9.67

Low $7.00

Middle $10.00

High $12.00

Analyst ratings

19 ratings
  • Strong Buy0
  • Buy18
  • Hold1
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.08−$0.06−$0.30−$0.25
Lowest estimate−$0.08−$0.06−$0.39−$0.33
Highest estimate−$0.08−$0.06−$0.20−$0.17
Number of analysts2123
A year ago−$0.11−$0.06−$0.56—
Growth vs a year ago+30.9%+0.0%+47.1%—

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$1.25M$9.48M
Lowest estimate$0.00$0.00$951870.00$7.22M
Highest estimate$0.00$0.00$1.55M$11.74M
Number of analysts0023
A year ago$0.00$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Aldeyra Therapeutics, Inc.. Aldeyra Therapeutics, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALDX20 companies · 6 funds
Compare ALDX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACIUAC Immune S.A.HealthcareBiotechnology$213.7M
AMRNAmarin Corporation plcHealthcareDrug Manufacturers - General$232.9M
ANROAlto Neuroscience, Inc.HealthcareBiotechnology$1.0B
CADLCandel Therapeutics, Inc.HealthcareBiotechnology$417.3M
CLLSCellectis S.A.HealthcareBiotechnology$103.8M
CTNMContineum Therapeutics, Inc. Class A Common StockHealthcareBiotechnology$326.7M
GNLXGenelux CorporationHealthcareBiotechnology$107.7M
KYTXKyverna Therapeutics, Inc.HealthcareBiotechnology$283.2M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
PYC.AXPYC Therapeutics LimitedHealthcareASX—
OBXObsidian Therapeutics Inc.HealthcareNASDAQ$12.7M
OCC.AXOrthocell LimitedHealthcareASX—
OCEAOcean Biomedical, Inc.HealthcarePNK$1.2M
OCGNOcugen, Inc.HealthcareNASDAQ$250.8M
OCSOculis Holding AGHealthcareNASDAQ$456.2M
OCULOcular Therapeutix, Inc.HealthcareNASDAQ$1.3B
ODTXOdyssey Therapeutics, Inc.HealthcareNASDAQ$912.3M
OGENOragenics, Inc.HealthcareAMEX$852,760
OKUROnKure Therapeutics, Inc.HealthcareNASDAQ$114.2M
ETFs holding Aldeyra Therapeutics, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
IWCiShares Micro-Cap ETF$1.2B in assets0.01%
VHTVanguard Health Care ETF$19.1B in assets0.00%
PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.00%
QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.31%

Largest holders first, then the funds most concentrated in ALDX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Aldeyra Therapeutics, Inc., and how their positions are changing. At a $40.5M market value, institutional positions materially move Aldeyra Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Aldeyra Therapeutics, Inc. executives and directors. Shares of Aldeyra Therapeutics, Inc. have traded between $1.14 and $7.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Aldeyra Therapeutics, Inc.. Coverage tracks Aldeyra Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Aldeyra Therapeutics, Inc.

ALDX AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1